Havrix®
Sponsors
GlaxoSmithKline, Canadian Immunization Research Network
Conditions
Haemophilus Influenzae Type bHepatitis AMeaslesMeasles-Mumps-Rubella VaccineMeningococcal Serogroup BMumpsNeisseria MeningitidisRubella
Phase 2
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
CompletedNCT00578175
Start: 2007-11-20End: 2009-03-17Updated: 2018-10-09
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
CompletedNCT00861744
Start: 2009-06-03End: 2012-06-18Updated: 2020-01-03
Phase 3
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
CompletedNCT00197015
Start: 2003-10-06End: 2009-06-09Updated: 2018-07-31
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age
CompletedNCT01978093
Start: 2014-02-01End: 2016-03-18Updated: 2018-09-14
Phase 4
Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults
CompletedNCT02583412
Start: 2015-09-30End: 2017-06-30Updated: 2019-01-31
Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel
WithdrawnNCT03183492
Start: 2018-05-07End: 2019-01-28Updated: 2018-03-02